Curis Company Profile (NASDAQ:CRIS)

About Curis

Curis logoCuris, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CRIS
  • CUSIP: 23126910
Key Metrics:
  • Previous Close: $1.69
  • 50 Day Moving Average: $1.70
  • 200 Day Moving Average: $1.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.57
  • P/E Growth: 0.00
  • Market Cap: $218.81M
  • Outstanding Shares: 129,472,000
  • Beta: 1.75
Additional Links:
Companies Related to Curis:

Analyst Ratings

Consensus Ratings for Curis (NASDAQ:CRIS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (195.86% upside)

Analysts' Ratings History for Curis (NASDAQ:CRIS)
DateFirmActionRatingPrice TargetDetails
6/13/2016FBR & CoReiterated RatingBuyView Rating Details
6/3/2016Robert W. BairdReiterated RatingOutperform$7.00View Rating Details
5/5/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details
3/1/2016SunTrust Banks Inc.Initiated CoverageBuy$3.00View Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details
7/6/2015Oppenheimer Holdings Inc.Reiterated RatingOutperformView Rating Details
5/16/2015Stifel NicolausReiterated RatingHoldView Rating Details
(Data available from 8/27/2014 forward)


Earnings History for Curis (NASDAQ:CRIS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.09)($0.09)$2.05 million$1.70 millionViewListenView Earnings Details
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.04)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.05)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.06)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details
5/8/2012$0.02$0.03ViewN/AView Earnings Details
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Curis (NASDAQ:CRIS)
Current Year EPS Consensus Estimate: $-0.38 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.08)($0.05)($0.07)
Q2 20164($0.10)($0.05)($0.08)
Q3 20164($0.13)($0.07)($0.10)
Q4 20164($0.12)($0.08)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Curis (NASDAQ:CRIS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.00View SEC Filing  
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.00View SEC Filing  
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00View SEC Filing  
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00View SEC Filing  
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00View SEC Filing  
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00View SEC Filing  
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00View SEC Filing  
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.00View SEC Filing  
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00View SEC Filing  
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.00View SEC Filing  
8/16/2013James McnabDirectorSell50,000$4.00$200,000.00View SEC Filing  
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Curis (NASDAQ:CRIS)
News IconMagnifying Stocks of Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS) - August 23 at 4:32 PM
News IconLet's Take a Closer Look at Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS) - August 23 at 8:37 AM
News IconPenny Stock Alert - Update & Review on This Stock: Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS) - August 19 at 8:30 PM
News IconInstitutions Have Decreased Their Ownership of Curis, Inc. (NASDAQ:CRIS) - Post News (NASDAQ:CRIS) - August 19 at 3:30 PM
News IconCuris, Inc. (NASDAQ:CRIS) Shares in Focus According to the Crowd & Analysts - Post News (NASDAQ:CRIS) - August 19 at 10:20 AM
News IconA Closer Look at Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS) - August 16 at 9:42 PM
News IconSmall Cap Update on: Curis, Inc. (NASDAQ:CRIS) - Duncan Research (NASDAQ:CRIS) - August 15 at 11:40 AM logoETF’s with exposure to Curis, Inc. : August 15, 2016 (NASDAQ:CRIS) - August 15 at 11:40 AM logoCuris, Inc. :CRIS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:CRIS) - August 12 at 4:26 PM logoCURIS INC Financials (NASDAQ:CRIS) - August 11 at 4:32 PM logoEdited Transcript of CRIS earnings conference call or presentation 4-Aug-16 12:30pm GMT (NASDAQ:CRIS) - August 5 at 4:25 PM logoCuris' (CRIS) CEO Ali Fattaey on Q2 2016 Results - Earnings Call Transcript (NASDAQ:CRIS) - August 4 at 4:36 PM logoEARNINGS SUMMARY: Details of Curis Inc Q2 Earnings Report (NASDAQ:CRIS) - August 4 at 10:49 AM logoCuris Reports Second Quarter 2016 Financial Results (NASDAQ:CRIS) - August 4 at 10:49 AM logoCuris Inc.: View all press releases » (NASDAQ:CRIS) - August 4 at 10:49 AM logoCuris reports 2Q loss (NASDAQ:CRIS) - August 4 at 10:49 AM logoCuris to Release Second Quarter 2016 Financial Results and Hold Conference Call on August 4, 2016 (NASDAQ:CRIS) - July 28 at 7:28 AM
News IconTrading the Biotech News: Curis, Inc. (NASDAQ:CRIS), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - The Voice Registrar (NASDAQ:CRIS) - July 27 at 4:28 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Curis, Inc. (NASDAQ:CRIS) - TGP (NASDAQ:CRIS) - July 22 at 4:28 PM
News IconCuris, Inc. (NASDAQ:CRIS) Could Reverse On Near Term Catalysts - Insider Financial (NASDAQ:CRIS) - July 22 at 4:28 PM logoETF’s with exposure to Curis, Inc. : July 19, 2016 (NASDAQ:CRIS) - July 19 at 12:14 PM
News IconHow Many Curis, Inc. (NASDAQ:CRIS)'s Analysts Are Bullish? - Consumer Eagle (NASDAQ:CRIS) - July 18 at 4:36 PM
News IconShares Moving Down on the Week: Curis, Inc. (NASDAQ:CRIS) - Engelwood Daily (NASDAQ:CRIS) - July 18 at 9:24 AM logoNext Weeks Broker Price Targets For Curis, Inc. (CRIS) - Fiscal Standard (NASDAQ:CRIS) - July 18 at 9:24 AM
News IconShares Experiencing a Downtrend: Curis, Inc. (NASDAQ:CRIS) - TGP (NASDAQ:CRIS) - July 16 at 6:07 AM
News IconCrowd Rating and Earnings Recap for Curis, Inc. (NASDAQ:CRIS) - Telanagana Press (NASDAQ:CRIS) - July 15 at 9:56 AM
News IconCuris, Inc. (NASDAQ:CRIS) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:CRIS) - July 14 at 8:19 AM
News IconStock Volatility Focus for: Curis, Inc. (NASDAQ:CRIS) - Engelwood Daily (NASDAQ:CRIS) - July 12 at 8:43 AM
News IconStock on the Rise for the Quarter: Curis, Inc. (NASDAQ:CRIS) - Engelwood Daily (NASDAQ:CRIS) - July 12 at 8:43 AM
News IconCuris, Inc. (NASDAQ:CRIS) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:CRIS) - July 12 at 8:43 AM
News IconTrading Performance and Target Watch for Curis, Inc. (NASDAQ:CRIS) - Press Telegraph (NASDAQ:CRIS) - July 12 at 8:43 AM
News IconCuris Inc (NASDAQ:CRIS) Institutional Investor Sentiment Trend - Consumer Eagle (NASDAQ:CRIS) - July 12 at 8:43 AM logoCuris, Inc. (CRIS) Updated Price Targets - FTSE News (NASDAQ:CRIS) - July 8 at 4:26 PM
News IconWall Street Ratings and Target Price Views on Curis, Inc. (NASDAQ:CRIS) - Telanagana Press (NASDAQ:CRIS) - July 8 at 11:18 AM
News IconStock Moving Up in Trading: Curis, Inc. (NASDAQ:CRIS) - Telanagana Press (NASDAQ:CRIS) - July 7 at 9:38 PM
News IconHeightened Volatility Check on: Curis, Inc. (NASDAQ:CRIS) - Engelwood Daily (NASDAQ:CRIS) - July 7 at 9:38 PM logoFast Moving Stocks: DuPont Fabros Technology, (NYSE:DFT), Curis, Inc. (NASDAQ:CRIS), Bristol-Myers Squibb ... - KC Register (NASDAQ:CRIS) - July 6 at 10:13 PM
News IconShare Performance Recap for: Curis, Inc. (NASDAQ:CRIS) - Press Telegraph (NASDAQ:CRIS) - July 6 at 10:13 PM
News IconStock Rating Watch and Earnings Insight for Curis, Inc. (NASDAQ:CRIS) - Press Telegraph (NASDAQ:CRIS) - July 6 at 10:13 PM logoCuris, Inc. (CRIS) Current Analyst Ratings - Fiscal Standard (NASDAQ:CRIS) - July 6 at 10:13 PM logoShining on Major News: Curis, Inc. (NASDAQ:CRIS), AT&T, Inc. (NYSE:T), Ciber, Inc. (NYSE:CBR), Regeneron ... - KC Register (NASDAQ:CRIS) - July 1 at 9:33 PM
News IconShare Update and Earnings Review for Curis, Inc. (NASDAQ:CRIS) - Press Telegraph (NASDAQ:CRIS) - June 30 at 11:26 AM
News IconCuris, Inc. (NASDAQ:CRIS) Company Rating and Target Watch - Telanagana Press (NASDAQ:CRIS) - June 30 at 11:26 AM logoMorning Watch List: Dimension Therapeutics, Inc. (NASDAQ:DMTX), Curis, Inc. (NASDAQ:CRIS), Itau Unibanco (NYSE ... - KC Register (NASDAQ:CRIS) - June 27 at 4:24 PM
News IconCuris, Inc. (NASDAQ:CRIS) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:CRIS) - June 27 at 4:24 PM
News IconHow Many Curis, Inc. (NASDAQ:CRIS)'s Analysts Are Bullish? - Press Telegraph (NASDAQ:CRIS) - June 26 at 4:05 PM logoNew Broker Ratings For Curis, Inc. (CRIS) - FTSE News (NASDAQ:CRIS) - June 23 at 3:16 PM logoNotable Mover: Curis, Inc. (NASDAQ:CRIS) - iStreetWire (NASDAQ:CRIS) - June 22 at 4:34 PM logoWhat’s so ‘groundbreaking’ about Curis’ new cancer drug that just began human trials? (NASDAQ:CRIS) - June 22 at 2:05 PM logoCuris May Make A Splash In Immune Checkpoint Inhibition - Seeking Alpha (NASDAQ:CRIS) - June 22 at 9:07 AM


Curis (NASDAQ:CRIS) Chart for Saturday, August, 27, 2016

Last Updated on 8/27/2016 by Staff